Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients

Prostaglandins and Other Lipid Mediators

Volumn 78, Issue 1-4, 2005, Pages 194-201

  Daza, L ^a,c   Kornhauser, C ^b   Zamora, L ^a   Flores, J ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b UNIVERSITY OF GUANAJUATO   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Captopril; Lupus nephritis; Prostaglandin E2; Proteinuria; Thromboxane B2

Indexed keywords

CAPTOPRIL; CYCLOPHOSPHAMIDE; PREDNISONE; PROSTAGLANDIN E2; THROMBOXANE B2;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PLASMA FLOW; LUPUS ERYTHEMATOSUS NEPHRITIS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION;

ADOLESCENT; ADULT; CAPTOPRIL; CYCLOPHOSPHAMIDE; DINOPROSTONE; HUMANS; LUPUS NEPHRITIS; PREDNISOLONE; PROTEINURIA; THROMBOXANE B2;

EID: 27744543442     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2005.08.001     Document Type: Article

References (45)

1. M.C. Carrol The lupus paradox: natural immunity is protective against disease Kidney Int 65 2004 1540
2. D. Pisetski Systemic Lupus erythematosus, epidemiology, pathology and pathogenesis J. Klippel Primer on the rheumatic diseases 1997 Arthritis Foundation Ed. Atlanta Georgia 246 251
3. L. Martins, G. Rocha, and A. Rodríguez Lupus Nephritis: a retrospective review of 78 cases from a single center Clin Nephrol 57 2002 114 119
4. S.M. Korbet, E.J. Lewis, M.M. Schwartz, M. Reichlin, J. Evans, and R.D. Rohde Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group Am J Kidney Dis 35 2000 904 914
5. G. Gamba, L. Quintanilla, M.D. Del Bosque, A. Chew-Wong, and R. Correa-Rotter Clinical course and prognostic factors in lupus nephropathy Rev Invest Clin 52 2000 397 405
6. R. Cervera, M. Khamashta, J. Font The European Working Party on Systemic Lupus Erythematosus Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients Medicine 72 1993 113 124
7. M. Petri, Perez-Gutthann, J. Longenecker, and M. Hochberg Morbidity of systemic lupus erythematosus role of race and socioeconomic status Am J Med 91 1991 345 353
8. M. Abu Shakra, M. Urowitz, D. Gladman, and J. Gough Mortality studies in systemic lupus erythematosus results from a single center. I. Causes of death J Rheumatol 22 1995 1259 1264
9. R. Herrera-Esparza, O. Barbosa, H. Villalobos, and E. Avalos Renal expression of IL-6 and TNF alpha genes in lupus nephritis Lupus 7 1998 134 138
10. M. Nakajima, S. Kawahara, and Y. Sakagami Immunogold labeling of cytokines in glomeruli in children with various renal diseases Nephron 83 1999 132 138
11. I. Badillo-Almaraz, L. Daza, E. Avalos-Díaz, and R. Herrera-Esparza Glomerular expression of FAS ligand and BAX mRNA in lupus nephritis Autoimmunity 34 2001 283 289
12. E.W. Inscho, P.K. Carmines, and L.G. Navar Prostaglandin influences on afferent arteriolar responses to vasoconstrictor agonist Am J Physiol 259 1 Pt 2 1990 F157 F163
13. J.D. Imig, M.D. Breyer, and R.M. Breyer Contribution of PG EP(2) receptors to renal microvascular reactivity in mice Am J Physiol Renal Physiol 283 3 2002 F415 F422
14. R.L. Hebert, H.R. Jacobson, D. Fredin, and M.D. Breyer Evidence that separate PGE2 receptors modulate water and sodium transport in rabbit cortical collecting duct Am J Physiol 265 1993 F643 F650
15. A. Fuson, P. Komlosi, T. Unlap, B.P. Darwin, and J. Peti-Peterdi Immunolocalization of a microsomal prostaglandin E synthase in rabbit kidney Am J Physiol Renal Physiol 285 2003 F558 F564
16. A. Schneider, Y. Zhang, and M. Zhang Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney Kidney Int 65 2004 1205 1213
17. A.J. Herrera, P. Reyes, and G. Lopez Inhibition of prostaglandin synthesis results in suppression of renal functional reserve in lupus nephritis Rev Invest Clin 39 1987 107 114
18. A. Pierucci, B. Simonetti, and G. Pecci Improvement of renal function with selective thromboxane antagonism in lupus nephritis N Engl J Med 320 1989 421 425
19. R.F. Spurney, R.J. Bernstein, P. Ruiz, D.S. Pisetsky, and T.M. Coffman Physiologic role for enhanced renal thromboxane production in murine lupus nephritis Prostaglandins 42 1991 15 28
20. T. Yoshida, H. Kameda, Y. Ichikawa, T. Tojo, and M. Homma Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis J Rheumatol 23 1996 1719 1724
21. R.M. Zusman Effects of converting-enzyme inhibitors on the renine-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity Am J Kidney Dis 10 1987 13 23
22. A. Dendorfer, S. Wolfrum, and P. Dominiak Pharmacological and cardiovascular implications of the kinin-kallikrein system Jpn J Pharmacol 79 1999 403 426
23. G. Rostoker, A. Ben Maadi, P. Remy, P. Lang, G. Lagrue, and B. Weil Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment Nephrol Dial Transplant 10 1995 25 29
24. H.H. Parving, E. Hommel, B.R. Jensen, and H.P. Hansen Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients Kidney Int 60 2001 228 234
25. X. Xiao, P. Gan, M. Yu, J. Li, and Q. Han Effect of captopril on renal hemodynamics and renal prostaglandins in early type II diabetic patients with normo or microalbuminuria Chin Med Sci J 11 1996 170 173
26. M. Allon, C.B. Pasque, and M. Rodriguez Acute effects of captopril and ibuprofen on proteinuria in patients with nephrosis J Lab Clin Med 116 1990 462 468
27. R. Romero, I. Salinas, and A. Lucas Renal function changes in microalbuminuric normotensive type II Diabetic patients treated with angiotensin-converting enzyme inhibitors Diab Care 16 1993 597 600
28. Y. Shapira, F. Mor, A. Friedler, A.J. Wysenbeek, and A. Weinberger Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome Ann Rheum Dis 49 1990 725 727
29. H. Herlitz, C. Svalander, A. Tarkowski, and G. Westberg Effect of captopril on murine systemic lupus erythematosus disease J Hypertens Suppl 6 4 1988 s684 s686
30. H. Herlitz, A. Tarkowski, C. Svalander, R. Volkmann, and G. Westberg Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice Int Arch Allergy Appl Immunol 85 1988 272 277
31. M.A. Gonzalez-Gay, C. Garcia-Porrua, L. Lopez Lazaro, and A. Olive Successful response to captopril in severe nephrotic syndrome secondary to lupus nephritis Nephron 80 1998 353 354
32. C. Odaka, and T. Mizuochi Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals Clin Exp Immunol 121 2000 515 522
33. E.M. Tan, A.S. Cohen, and J.F. Fries The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1982 1271 1277
34. H. Yokoyama, T. Wada, A. Hara The Kanazawa Study Group for Renal Diseases and Hypertension The outcome and new ISN/RPS 2003 classification of lupus nephritis in Japanese Kidney Int 66 2004 2382 2388
35. R. Kelly, W. Graham BJM, and M.J. O'Sullivan Measurement of PGE2 as the methyl oxime by radioimmunoassay using a novel iodinated label Prostaglandins, Leukot Essent Fatty Acids 37 1989 187 191
36. E. Granstrom, and H. Kindahl Radioimmunoassay of prostaglandins and thromboxanes Adv Prostaglandin Thromboxane Res 5 1978 119 210
37. H.G. Morris, N.A. Sherman, and F.T. Shepperdson Variables associated with radioimmunoassay of prostaglandins in plasma Prostaglandins 21 1981 771 788
38. G. Hill, M. Delahousse, D. Nochy, Ch Mandet, and J. Bariéty Proteinuria and tubulointerstitial lesions in lupus nephritis Kidney Int 60 2001 1893 1903
39. S. Tomasoni, M. Noris, and S. Zappella Up-regulation of renal and systemic cyclooxigenase-2 in patients with active lupus nephritis J Am Soc Nephrol 9 1998 1202 1212
40. H.F. Chen, and R.C. Harris Cyclooxigenases, the kidney and hypertension Hypertension 43 2004 525 530
41. H.F. Cheng, S.W. Wang, M.Z. Zhang, J.A. McKanna, R. Breyer, and R.C. Harris Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxigenase-1 Am J Physiol Regul Integr Comp Physiol 283 3 2002 R638 R646
42. V.E. Kelley, S. Sneve, and S. Musinski Increased renal thromboxane production in murine lupus nephritis J Clin Invest 77 1986 252 259
43. T. Yoshida, Y. Ichikawa, T. Tojo, and M. Homma Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor DP 1904 Lupus 5 1996 129 138
44. D.A. De Albuquerque, V. Saxena, and D.E. Adams An ACE inhibitor reduces th2 cytokines and TGF beta 1 and TGF beta 2 isoforms in murine lupus nephritis Kidney Int 65 2004 846 859
45. M. Breyer, H. Jacobson, R. Breyer, and Functional molecular aspects of renal prostaglandin receptors J Am Soc Nephrol 7 1996 8 17